HI
SVA

Harbour Investments’s Sinovac Biotech, Ltd SVA Stock Holding History

Harbour Investments’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503 Sell
78
-5
-6% -$32 ﹤0.01% 4373
2026
Q1 		$542 Buy
+83
New +$542 ﹤0.01% 4237
2021
Q4 		– Sell
-180
Closed -$1K – 4062
2021
Q3 		$1K Hold
180
– – ﹤0.01% 3692
2021
Q2 		$1K Hold
180
– – ﹤0.01% 3735
2021
Q1 		$1K Buy
+180
New +$1K ﹤0.01% 3572

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Harbour Investments's SVA Position: Q2 2026 in Review

Harbour Investments reduced its Sinovac Biotech, Ltd (SVA) stake by 6% in Q2 2026, selling an estimated $32 and leaving 78 shares worth $503. The position accounts for ﹤0.01% of the portfolio, ranked #4373.

Harbour Investments first reported a position in SVA in Q1 2021 and has held it in 5 quarters since. The position peaked at $1K in Q3 2021. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

  • Harbour Investments held 78 shares of Sinovac Biotech, Ltd worth $503 as of Q2 2026.
  • Harbour Investments sold 5 Sinovac Biotech, Ltd shares in Q2 2026, an estimated $32.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4373 holding.
  • Harbour Investments first reported a position in Sinovac Biotech, Ltd in Q1 2021 and has held it in 5 quarters since.
  • Harbour Investments's Sinovac Biotech, Ltd position peaked at $1K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.